Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Blood Cancer J
; 14(1): 35, 2024 Mar 05.
Article
em En
| MEDLINE
| ID: mdl-38443345
ABSTRACT
The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies. The overall response rate (ORR) in our cohort was 62%, with a ≥ very good partial remission (VGPR) rate of 51%. The ORR in patients with and without prior BCMA-targeted therapies was 54% vs 67%, respectively (p = 0.23). At a median follow-up of 3.5 months (range, 0.39-10.92), the estimated 3 month and 6 month progression free survival (PFS) was 57% (95% CI, 48%, 68%) and 52% (95% CI, 42%, 64%) respectively. The incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) was 56% and 11% respectively, with grade ≥3 CRS and ICANS noted in 3.5% and 4.6% of patients respectively. 78 unique infections were diagnosed in 44 patients, with the incidence of all-grade and grade ≥3 infections being 40% vs 26% respectively. Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a significantly lower infection risk on multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64; p = 0.001).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tetranitrato de Pentaeritritol
/
Anticorpos Biespecíficos
/
Neoplasias de Plasmócitos
/
Mieloma Múltiplo
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Blood Cancer J
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos